Canaccord Genuity Maintains a 'Buy' on Edwards Lifesciences (EW); Update from STS Tech Con; Expect Solid SAPIEN T/A Data
Tweet
Share
E-mailGet Alerts EW Hot Sheet
Price: $89.83 --0%
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 25
Rating Summary:
31 Buy, 14 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 25
Join SI Premium – FREE
Canaccord Genuity maintains a 'Buy' on Edwards Lifesciences (NYSE: EW) price target of $85.00.
Analyst, Jason R. Mills, said, "EW remains one of our two 2012 “Best Ideas.” We would be buyers of the stock at current levels, as we anticipate solid Cohort A T/A data to be presented this afternoon at the STS meeting in Florida, and expect an FDA Panel to recommend approval for both T/A and T/F once a Panel is called (expected March/April)."
"No new SAPIEN data was presented at yesterday's Tech Con (the prelude to the Society of Thoracic Surgeon meeting, which begins today); however, our checks with TAVI thought leaders indicate increasing expectations FDA will approve SAPIEN both trans-femoral (T/F) and trans-apical (T/A) in high risk (Cohort A) patients."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $79.18 yesterday.
Analyst, Jason R. Mills, said, "EW remains one of our two 2012 “Best Ideas.” We would be buyers of the stock at current levels, as we anticipate solid Cohort A T/A data to be presented this afternoon at the STS meeting in Florida, and expect an FDA Panel to recommend approval for both T/A and T/F once a Panel is called (expected March/April)."
"No new SAPIEN data was presented at yesterday's Tech Con (the prelude to the Society of Thoracic Surgeon meeting, which begins today); however, our checks with TAVI thought leaders indicate increasing expectations FDA will approve SAPIEN both trans-femoral (T/F) and trans-apical (T/A) in high risk (Cohort A) patients."
For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.
Shares of Edwards Lifesciences closed at $79.18 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Idex Corp. (IEX) Reiterated at Buy by Stifel
- Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS
- DA Davidson Starts Everus (ECG) at Buy
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
